Although whether penfluridol can prevent SET/PP2A-C binding needs be further addressed, our present findings strongly support repurposing penfluridol as a drug for treating AML, especially for the cancer types that are characterized by functional loss of the PP2A tumor suppressor. This evidence concerns the gene PTPA and neoplasm.